Edgewise boosted 1Q balance sheet with stock sale
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, ended the first quarter of 2025 with a proforma balance of $624.4 million, thanks in part to a $200 million stock sale in April.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Edgewise Therapeutics Inc., (Nasdaq: EWTX), a Boulder-based muscle-disease biopharmaceutical company, maintained a strong cash balance…
-
Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based muscle disease biopharmaceutical company, has reported a net…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based biopharmaceutical company that develops therapies for muscle disease,…
